Bayer Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Bill Anderson

Chief executive officer

€11.8m

Total compensation

CEO salary percentage	14.3%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	2.3yrs
Board average tenure	7.7yrs

Recent management updates

Recent updates

Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate

Aug 05

Is Bayer (ETR:BAYN) A Risky Investment?

Jun 28

Bayer (ETR:BAYN) Use Of Debt Could Be Considered Risky

Dec 07

Is Bayer (ETR:BAYN) A Risky Investment?

Aug 18

CEO Compensation Analysis

How has Bill Anderson's remuneration changed compared to Bayer's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	€12m	€2m	-€3b

Compensation vs Market: Bill's total compensation ($USD12.66M) is above average for companies of similar size in the German market ($USD5.58M).

Compensation vs Earnings: Insufficient data to compare Bill's compensation with company performance.

CEO

Bill Anderson (57 yo)

less than a year

Tenure

€11,804,104

Compensation

Mr. William N. Anderson, also known as Bill, is Member of Management Board of Bayer Aktiengesellschaft from April 1, 2023 and also serves as its Chairman of the Management Board and Chief Executive Officer...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
William Anderson	Chairman of the Management Board & CEO	less than a year	€11.80m	no data
Wolfgang Nickl	CFO & Member of Management Board	6yrs	€3.42m	no data
Heiko W. Schipper	Member of Management Board & President of the Consumer Health Division	6.1yrs	€3.39m	no data
Stefan Oelrich	Head of the Pharmaceuticals Division & Member of the Board of Management	5.4yrs	€3.43m	no data
Rodrigo Santos	Member of Management Board & President of the Crop Science Division	2.3yrs	€3.65m	no data
Heike Prinz	Chief Talent Officer	less than a year	€2.53m	no data
Julio Triana	Member of Management Board & President of Consumer Health Division	no data	no data	no data
Sebastian Guth	Chief Operating Officer	no data	no data	no data
Jost Reinhard	Head of Investor Relations	less than a year	no data	no data
Michael Preuss	Head of Communications	7.9yrs	no data	no data
Bernd-Peter Bier	Head of Group Finance	no data	no data	no data
Robert LaCaze	Executive VP & Head of the Oncology Strategic Business Unit	7.2yrs	no data	no data

2.3yrs

Average Tenure

55yo

Average Age

Experienced Management: BAYN's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Paul M. Achleitner	Member of Supervisory Board	22yrs	€225.00k	no data
Ertharin Cousin	Independent Member of the Supervisory Board	4.5yrs	€270.00k	no data
Heinz Webers	Employee Representative Member of Supervisory Board	2yrs	€205.00k	no data
Simone Bagel-Trah	Independent Member of Supervisory Board	10yrs	€227.00k	no data
Daniel Hartert	Chairman of Executive Board - Bayer Business Services	no data	no data	no data
Horst Baier	Independent Member of Supervisory Board	4yrs	€333.00k	no data
Heike Hausfeld	Vice Chairman of Supervisory Board	7yrs	€346.00k	no data
André van Broich	Member of Supervisory Board	12yrs	€271.00k	no data
Frank Löllgen	Member of Supervisory Board	8.4yrs	€268.00k	no data
Otmar Wiestler	Independent Member of Supervisory Board	9.5yrs	€237.00k	no data
Norbert Winkeljohann	Independent Chairman of Supervisory Board	5.9yrs	€509.00k	no data
Gunter Hilken	Chairman of Executive Board - Currenta	no data	no data	no data

7.7yrs

Average Tenure

65.5yo

Average Age

Experienced Board: BAYN's board of directors are considered experienced (7.7 years average tenure).

Bayer Management

Management criteria checks 2/4

Key information

Recent management updates

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer AG Announces Management Changes

Bayer AG Announces CEO Changes

Recent updates

Upcoming dividend of €0.11 per share

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Price target decreased by 7.7% to €42.48

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Dividend of €0.11 announced

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Are Investors Undervaluing Bayer Aktiengesellschaft (ETR:BAYN) By 42%?

Williams Hart & Boundas Wins Against Bayer

Price target decreased by 7.7% to €51.57

Price target decreased by 7.6% to €57.57

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 13%

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

Consensus EPS estimates fall by 11%

New minor risk - Profit margin trend

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Consensus EPS estimates fall by 12%

Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 24%

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Initiates Phase III Studies with Investigational Compound Agent Gadoquatrane

Is Bayer (ETR:BAYN) A Risky Investment?

FDA Approves Bayer's Ultravist® (iopromide) Injection for contrast-enhanced Mammography

Bayer to Investigate Finerenone in Phase Iii Study in Adults with Chronic Kidney Disease Associated with Type 1 Diabetes

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Upcoming dividend of €2.40 per share at 4.0% yield

Consensus EPS estimates fall by 10%

Full year 2022 earnings: EPS misses analyst expectations

Bayer Aktiengesellschaft (XTRA:BAYN) completed the acquisition of Blackford Analysis Ltd.

Bayer AG Announces CEO Changes

Inclusive Capital Partners Provides Information to Shareholders of Bayer Aktiengesellschaft

Union Investment Criticizes Bayer AG Chairman for Lack of Engagement

Bayer Aktiengesellschaft (XTRA:BAYN) agreed to acquire Blackford Analysis Ltd.

Bayer Aktiengesellschaft to Report Q2, 2023 Results on Aug 08, 2023

Bayer (ETR:BAYN) Use Of Debt Could Be Considered Risky

Afrin WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays

Bayer Aktiengesellschaft (XTRA:BAYN) acquired Targenomix GmbH.

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Bayer Aktiengesellschaft Extends Development Program for Investigational Product Elinzanetant with Phase III Study in Breast Cancer Patients with Vasomotor Symptoms Caused by Endocrine Therapy

Bayer to Highlight Additional Analyses From Comprehensive KERENDIA® (finerenone) Clinical Trial Program at the American Society of Nephrology’s 2022 Kidney Week

Cinven Limited completed the acquisition of Environmental Science Professional business from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data from Innovative Science At ESMO Congress 2022

Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian

Bayer to Present Data From Cardiovascular Portfolio, Including a Late-Breaking Presentation From FIDELITY for KERENDIA® (finerenone) and New Phase IIb Data From PACIFIC Trial Program for the Oral Factor XIa Inhibitor asundexian

Is Bayer (ETR:BAYN) A Risky Investment?

Bayer Launches ForGround

U.S. FDA Approves Bayer's Additional Indication of NUBEQA (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Bayer Aktiengesellschaft (XTRA:BAYN) signed a shareholders agreement to acquire 65% stake in CoverCress Inc. from Bunge Ventures and Chevron U.S.A. Inc.

CEO Compensation Analysis

CEO